NIH-PA Author Manuscript

NIH-PA Author Manuscript

NIH-PA Author Manuscript

Mitochondria, calcium and cell death: A deadly triad in neurodegeneration

Fulvio Celsi[a,b], **Paola Pizzo**[c], **Marisa Brini**[d,e], **Sara Leo**[a,b], **Carmen Fotino**[a,b], **Paolo Pinton**[a,b], and **Rosario Rizzuto**[c,*]

a *Department of Experimental and Diagnostic Medicine, Section of General Pathology, Interdisciplinary Center for the Study of Inflammation (ICSI), Italy*

b *Emilia Romagna Laboratory BioPharmaNet, University of Ferrara, Via Borsari 46, 44100 Ferrara, Italy*

c *Department of Biomedical Sciences, University of Padova, Via Colombo 3, 35121 Padova, Italy*

d *Department of Biochemistry, University of Padova, Viale G. Colombo, 3 35131 Padova, Italy*

e *Department of Experimental Veterinary Sciences, University of Padova, Viale dell' Università 16, 35020 Legnaro, Italy*

Abstract

Mitochondrial Ca^{2+} accumulation is a tightly controlled process, in turn regulating functions as diverse as aerobic metabolism and induction of cell death. The link between Ca^{2+} (dys)regulation, mitochondria and cellular derangement is particularly evident in neurodegenerative disorders, in which genetic models and environmental factors allowed to identify common traits in the pathogenic routes. We will here summarize: i) the current view of mechanisms and functions of mitochondrial Ca^{2+} homeostasis, ii) the basic principles of organelle Ca^{2+} transport, iii) the role of Ca^{2+} in neuronal cell death, and iv) the new information on the pathogenesis of Alzheimer's, Huntington's and Parkinson's diseases, highlighting the role of Ca^{2+} and mitochondria.

Keywords

1. Mitochondria in calcium signalling

The notion that mitochondria are active players in cellular calcium homeostasis dates back to the demonstration of the chemiosmotic theory, based on the concept of a major proton electrochemical gradient that could drive the rapid accumulation of cations across the ion-impermeant mitochondrial inner membrane. Such a notion was corroborated by the direct measurement of Ca^{2+} uptake by isolated mitochondria, and the functional, albeit not molecular, elucidation of the transporters [1].

However, the experiments that in the 80s drove massive interest into calcium as a ubiquitous second messenger also led to the gradual decline in the attention on mitochondrial Ca^{2+} homeostasis. On the one hand, it appeared clear that the endoplasmic reticulum (ER), through resident Ca^{2+} channels (those sensitive to inositol 1,4,5 trisphosphate, IP_3R, and to the plant

* Corresponding author. Tel.: +39 0498276481; fax: +39 0498276049. E-mail address: E-mail: rosario.rizzuto@unipd.it (R. Rizzuto).

alkaloid ryanodine, RyR) acts as the intracellular pool of Ca^{2+} mobilized upon cell stimulation. On the other, the development of accurate fluorescent indicators for the measurement of Ca^{2+} concentration in living cells showed that cytosolic Ca^{2+} concentration fluctuates between approx. 0.1 μM at rest to 2–3 μM at the peak of the rise elicited by the opening of plasma membrane or ER Ca^{2+} channels. Under those conditions, the low affinity of the mitochondrial Ca^{2+} transporters should allow little Ca^{2+} uptake into the organelle. Thus, the prevalent notion was that mitochondrial Ca^{2+} accumulation is negligible in physiological conditions, and could become relevant only upon massive Ca^{2+} overload, that could take place in severe cellular dysfunction.

This situation was completely reversed when tools were developed that allowed the selective measurement of mitochondrial Ca^{2+} concentration ($[Ca^{2+}]_m$) in living cells. Targeting to mitochondria the Ca^{2+}-sensitive photoprotein aequorin [2] demonstrated that a rapid $[Ca^{2+}]_m$ peak, reaching values well above those of the bulk cytosol, parallels the $[Ca^{2+}]$ rise evoked in the cytoplasm by cell stimulation [3]. Similar conclusions could be reached also with fluorescent indicators, such as the positively charged Ca^{2+} indicator rhod 2 (that accumulates within the organelle) [4] and the more recently developed GFP-based fluorescent indicators [5]. With the latter probes, endowed with a much stronger signal than the photoprotein, single-cell imaging of organelle Ca^{2+} could be carried out [6]. With these tools in hands, not only the notion was confirmed that mitochondria promptly respond to cytosolic $[Ca^{2+}]$ rises, but also that the $[Ca^{2+}]_c$ oscillations, the typical response to agonists of many cell types, are paralleled by rapid spiking of $[Ca^{2+}]_m$, thus providing a frequency-mediated signal specifically decoded within the mitochondria, as clearly shown in hepatocytes [7], cardiomyocytes [8], and HeLa cells [9]. The apparent discrepancy between the promptness and amplitude of the mitochondrial Ca^{2+} response and the low affinity of the organelle transporters was reconciled by the demonstration that mitochondria are in close contact with the source of the cytosolic Ca^{2+} rise (i.e. the ER via IP$_3$Rs and RyRs and the plasma membrane via a wide variety of voltage- and agonist-sensitive Ca^{2+} channels). Thus, upon cell stimulation they are exposed to microdomains of high $[Ca^{2+}]$ that greatly exceed the values measured in the cytosol and well match the affinity of mitochondrial Ca^{2+} transporters [10].

As soon as the concept was established that a Ca^{2+} rise in the cytosol is paralleled by a cycle of mitochondrial Ca^{2+} uptake, and subsequent release (through the pathways that will be briefly described later), the identification of the functional significance of this process became a primary goal. Also in this task, the fine biochemical work carried out in the 70s provided a hypothesis to test: three key metabolic enzymes (the pyruvate, ketoglutarate and isocitrate dehydrogenases) were shown to be activated by Ca^{2+} by different mechanisms: in the case of pyruvate dehydrogenase through a Ca^{2+}-dependent dephosphorylation step, in the latter two cases through the direct binding of Ca^{2+} to the enzyme complex [11]. Recently, also some metabolite transporters were shown to be regulated by Ca^{2+} and participate in the enhancement of aerobic metabolism upon cell stimulation [12]. Thus, an obvious role for mitochondrial Ca^{2+} accumulation could be inferred, i.e. that of rapidly upregulating mitochondrial ATP production in stimulated cells. The possibility of directly monitoring, in parallel, Ca^{2+} and ATP levels within mitochondria and in the cytosol proved that this is indeed the case [13]. Interestingly, this route for controlling mitochondrial metabolic output proved to be affected in mitochondrial genetic disorders. In cybrids harboring the tRNA$_{lys}$ mutation of MERRF (myoclonic epilepsy with ragged-red fibers), mitochondrial Ca^{2+} responses were reduced, and, accordingly, ATP production upon cell stimulation, and the pharmacological correction of the Ca^{2+} alteration also restored the metabolic dysfunction [14,15].

In addition to the function of metabolic coupling, mitochondrial Ca^{2+} accumulation was shown to underlie a role for these organelles in shaping the spatio/temporal patterning of cytosolic Ca^{2+} rises. Mitochondria, distinctly from cytosolic proteins, are highly sophisticated, "tunable"

buffers that vary their activity in different phases and functional states of the cell; indeed, their number, shape, distribution [16] and most likely their responsiveness to Ca^{2+} [17] are controlled by converging signalling pathways. This Ca^{2+} buffering activity influences cytosolic Ca^{2+} signals in two conceptually different ways, i.e., *1)* by acting as high-capacity sinks placed on the way of a propagating Ca^{2+} wave and *2)* by clearing Ca^{2+} in restricted microdomains (such as the microenvironment of a Ca^{2+}channel). In the first case, spatial clusters of mitochondria have been demonstrated to isolate functionally distinct domains of polarized cells, namely, a mitochondrial "firewall" was shown to prevent the spread of Ca^{2+} signals from the apical (secretory) region of pancreatic acinar cell from the basolateral region, containing the nucleus [18]. Similarly, neuronal mitochondria have been shown to buffer $[Ca^{2+}]$ increases in defined cellular regions, e.g., the presynaptic motoneuron ending [19]. As to the second case, a thoroughly investigated example is the regulation of Ca^{2+} release through IP$_3$Rs. In *Xenopus* oocytes, the mitochondria energization state (and thus the capacity to accumulate Ca^{2+}) was shown to modify the propagating Ca^{2+} waves induced by IP$_3$ [20]. In permeabilized blowfly salivary glands, it was observed that perfusion of IP$_3$ induced ER $[Ca^{2+}]$ oscillations, the frequency of which increased with the dose of IP$_3$. Such an effect was observed only upon energization of mitochondria, implying a primary role of these organelles in regulating Ca^{2+} microdomains in the proximity of IP$_3$Rs and thus the oscillatory pace of stimulated cells [21]. In mammals, this effect has been seen in many cell systems, including hepatocytes, HeLa cells, astrocytes, and BHK cells. As to the cellular consequence, very different effects were observed given the bell-shaped sensitivity of IP$_3$Rs to Ca^{2+} concentration on the cytosolic side. In astrocytes and hepatocytes, cytosolic excitability appeared enhanced when mitochondrial Ca^{2+} uptake was inhibited, indicating that mitochondrial clearance of the Ca^{2+} microdomain reduced the positive Ca^{2+} feedback on the IP$_3$R and/or buffered substantial Ca^{2+} loads [22]. Conversely, in BHK cells, inhibition of mitochondrial Ca^{2+} uptake resulted in reduction of ER Ca^{2+} release [23], thus indicating that mitochondria prevent the Ca^{2+}-dependent inactivation of the channel.

The interest in the process of mitochondrial Ca^{2+} homeostasis dramatically increased when it became apparent that also cell death is causally linked to organelle Ca^{2+} loading. On the one hand, it was clear that cellular Ca^{2+} overload, such as that caused by hyperstimulation of ionotropic glutamate receptors, leads to Ca^{2+} cycling across the mitochondrial membranes, collapse of the proton gradient and bioenergetic catastrophe, thus leading to cell death by necrosis, as discussed in more detail later in this review. On the other hand, Ca^{2+} proved to sensitize cells to apoptotic challenges, acting on the mitochondrial checkpoint. This notion, subsequently confirmed by the study of other anti- and pro-apoptotic proteins, emerged from the analysis of the effect of Bcl-2 on Ca^{2+} signalling. We refer to other specifically focused reviews for a detailed coverage of this topic [24]. Briefly, we here summarize that Bcl-2, by partially emptying the ER Ca^{2+} store, reduces the release from this organelle and the loading of mitochondria. As a consequence, the efficacy of apoptotic challenges in opening the permeability transition pore (PTP), causing mitochondrial morphological alterations and releasing caspase cofactors, such as cytochrome c, is greatly reduced [25].

2. The basics of mitochondrial Ca²⁺ transport

For entering the mitochondrial matrix, Ca^{2+} needs to cross two lipid bilayers, the outer and inner mitochondrial membranes (Fig. 1). The outer mitochondrial membrane (OMM) is permeable to ions and small proteins (MW<10 kDa) due to the abundance of a large conductance channel, known as mitochondrial porin or voltage-dependent anion channel (VDAC). It should be noted, however, that the channel appears to be gated in vivo, and permeability is controlled by ATP and other regulatory factors [26]. Ca^{2+} diffusion through the OMM was thus traditionally considered not to be a limiting factor in mitochondrial Ca^{2+} uptake. Recent data showed that the availability and selective placement of VDAC channels

at ER/mitochondria contact sites facilitate mitochondrial Ca^{2+} accumulation, in keeping with the idea that the latter process requires the fast and efficient transfer of Ca^{2+} microdomains from the mouth of the Ca^{2+} channels located in neighbouring ER or plasma membranes to the transporters of the ion-impermeant inner membrane (IMM) [27]. The IMM is an ion-impermeable membrane, with a much larger extension of the OMM (and consequent formation of foldings into the internal space, known as cristae). The activity of respiratory chain complexes allows the translocation of H^+ in the space between the two membranes, which consequently generates an electrochemical gradient ($\Delta\mu H$) composed of a chemical (ΔpH) and electrical ($\Delta\psi H$) component. In mitochondria, most of the $\Delta\mu H$ established by the respiratory chain is supposed to be in the form of $\Delta\psi H$ (around -180 mV), which provides a huge driving force for Ca^{2+} entry into the organelle. Indeed, collapse of the $\Delta\psi H$ by protonophores, such as p-[trifluoromethoxyl]-phenyl-hydrazone (FCCP), abolishes mitochondrial Ca^{2+} uptake.

Mitochondrial Ca^{2+} traffic takes place essentially through two pathways: i) an electrogenic pathway, the mitochondrial Ca^{2+} uniporter (MCU), corresponding to the channel activity demonstrated by Clapham et al. [28] that acts to equilibrate Ca^{2+} with its electrochemical gradient, and thus accumulates the cation into the matrix; ii) two exchangers (with H^+ and Na^+, mostly expressed in nonexcitable and excitable cells, respectively), that utilize the electrochemical gradient of the monovalent cations to prevent the attainment of electrical equilibrium (that would imply, for a mitochondrial membrane potential, $\Delta\psi_m$, of -180 mV and a cytosolic Ca^{2+} concentration of 0.1 μM, accumulation of Ca^{2+} into the matrix up to 0.1 M).

Numerous works has given the biochemical properties of these two pathways, and it is possible to summarize as it follows:

i. Given the huge driving force for accumulation, studies in isolated organelles with clamped $\Delta\Psi$ (by establishing K^+ diffusion potentials with valinomycin in non-respiring mitochondria) allowed to estimate a $V_{max}>1400$ nmol Ca^{2+} (mg protein)$^{-1}$ min^{-1} and an apparent $K_m<10$ μM in sucrose-based media [29]. Also in isolated mitochondria, a number of inhibitors were identified. Ruthenium compounds (typically Ruthenium Red, RR), represent a class of non-competitive inhibitors, but unfortunately their poor permeability across cellular membranes has made it of little use in studies in intact cells. A second class of inhibitors is divalent cations that are themselves transported by the uniporter (e.g. Sr^{2+}, Mn^{2+}, Ba^{2+} and lanthanides).

ii. As to the efflux pathways, studies in isolated organelles allowed to estimate their properties. The mitochondrial $Na+/Ca^{2+}$ exchanger (mNCX) has a V_{max} ranging between 2.6 (liver) and 18 nmol Ca^{2+} (mg protein)$^{-1}$ min^{-1} (heart). The dependence on Na^+ is sigmoidal, with typical K_m values of about 8–10 mM Na^+. Ca^{2+} efflux is inhibited by Sr^{2+}, Ba^{2+}, Mg^{2+} or Mn^{2+}, and by a variety of compounds of pharmacological interest such as diltiazem, verapamil and other blockers of the voltage-dependent calcium channels, and more specifically by CGP37157 [30]. As to the H^+/Ca^{2+} exchanger (mHCX), (1) it saturates at Ca^{2+} loads of 25 nmol (mg protein)$^{-1}$; (2) its V_{max} is not influenced by the concentration of inorganic phosphate and does not exceed a rate of 1.2 nmol Ca^{2+} (mg protein)$^{-1}$ min^{-1}; and (3) it extrudes Ca^{2+} against a gradient that is much higher than thermodynamically permissible for an electroneutral H^+/Ca^{2+} exchanger [31]. Thus, either Ca^{2+} efflux occurs via a nH^+/Ca^{2+} exchanger with $n>2$, or it has an active component. Accordingly, Ca^{2+} efflux is inhibited rather than stimulated by small depolarizations [32].

2.1. The permeability transition pore

This high-conductance channel (PTP) mediating mitochondrial swelling, postulated on the basis of experimental evidence dating back more than 40 years [33], has attracted enormous

interest in the last decade, when its role in mitochondrial dysfunction and mitochondria-dependent cell routes has become clear. It is a high-conductance, non-selective channel that exhibits a prominent dependence on matrix Ca^{2+} and is inhibited by Cyclosporin A (CsA). Reversible PTP openings have been resolved both in individual isolated mitochondria [34] and in intact cells [35]. PTP could play a role in various conditions. Long-lasting openings, triggered by apoptotic challenges and potentiated by Ca^{2+}-mediated cellular signals [36] cause morphological transitions of mitochondria underlying the release of caspase cofactors into the cytosol, and the initiation of the cell death process. Conversely, given the large size and lack of selectivity of the PTP (providing charge compensation within the channel and allowing maximal Ca^{2+} flux at zero potential) brief PTP openings could allow at least in principle rapid Ca^{2+} release from the organelle [37].

3. Calcium routes to neurodegeneration

It was hypothesized already in the 70s that prolonged stimulation of N-methyl-D-aspartate (NMDA) ionotropic glutamate receptors can induce massive cell death in the brain (excitotoxicity), by causing Ca^{2+} and Na^+ overload in post-synaptic neurons [38]. Excitotoxicity plays a central role in promoting cell death during neuronal ischemia and substantial work has been placed in clarifying the different phases of the process, and their reversibility, and the potential pharmacological targets. It is now accepted that a primary Ca^{2+} increase occurs, as a consequence of direct entry through NMDA receptors, but also following depolarization, and hence opening of voltage-gated Ca^{2+} channels, release from internal stores and reversal of the plasma membrane Na^+/Ca^{2+} exchanger (NCX). Cell death, however, does not depend on this initial Ca^{2+} rise, but rather invariably follows a delayed massive accumulation of Ca^{2+}, occurring a few hours after the toxic challenge and representing a no-return transition into the death process. Recent work has highlighted events occurring in the interphase between the two Ca^{2+} rises, and suggested a progression route into the secondary Ca^{2+} overload and delayed cell death. Specifically, Bano et al. [39] showed that calpain-mediated cleavage on NCX is a critical step for allowing the delayed Ca^{2+} deregulation: inhibition of NCX cleavage protects from excitotoxic challenges, and conversely downregulation of the exchanger sensitizes to sub-lethal stimuli. As to mitochondria, direct measurement of matrix Ca^{2+} showed that the impairment of their Ca^{2+} uptake capacity is downstream of the delayed Ca^{2+} dysregulation, and not the cause of it. Thus, the delayed Ca^{2+} increase is not due to the sudden discharge from the mitochondrial buffer that still retains the capacity to accumulate Ca^{2+}. Rather, the delayed, massive influx of Ca^{2+} into the cell leads to organelle Ca^{2+} overload, collapse of the electrochemical proton gradient and bioenergetic catastrophe, leading to necrotic cell death [40].

Interestingly, such a commitment mechanism appears to closely match an emerging paradigm clarified in a number of apoptotic routes. Indeed, we and other showed that mitochondrial involvement in apoptosis (morphological transitions and release of caspase cofactors) often utilizes Ca^{2+} as a key sensitizing factor. In agreement with this notion, Bcl-2 reduces the state of filling of intracellular Ca^{2+} stores, thereby reducing mitochondrial loading upon physiological and pathological challenges and protecting cells from apoptotic death [25]. The pro-apoptotic protein Bax antagonizes this signalling effect, by augmenting the state of filling of intracellular Ca^{2+} stores [41]. In addition, closely mimicking the data described above in excitotoxicity, early cleavage of plasma membrane Ca^{2+} pumps (PMCA) by caspases was shown to greatly enhance the efficacy of apoptotic challenges in neurons [39] and hepatocytes [42]. In this context, one can envision a common route to neurodegeneration in neurons, in which Ca^{2+} plays an important regulatory role and eventually, by affecting the mitochondrial checkpoint, renders cell death obligatory. Thus, while the fate into a rapid necrotic outcome or a more controlled apoptotic elimination will depend on the intensity of the insult and on the bioenergetic balance of the cell, the observation of common signalling themes and molecular

targets highlights the extensive crosstalk between the different death pathways and the potential strategies for pharmacological intervention.

4. Looking into complex models: the pathogenesis of neurodegenerative disorders

4.1. Alzheimer's disease (AD)

Alzheimer's disease (AD) is a devastating neurological disorder clinically characterized by impairment of cognitive function and changes in behavior and personality. Morphological hallmarks of the pathology are cortical and hippocampal atrophy, accumulation of abnormal fibers in neuronal cell bodies (neurofibrillary tangles composed of a hyperphosphorylated form of the microtubular protein tau), and the presence, in the extracellular space, of senile plaques, the major component of which is the peptide β-amyloid (Aβ) in two most frequent forms, Aβ40 and Aβ42. These derive from the transmembrane protein APP (Amyloid Precursor Protein), that can be alternatively processed by three different enzymes, named α, β, and γ secretases. The combined action of β and γ secretases leads to the formation of a soluble fragment (sAPPβ) and of Aβ, together with its cytosolic counterpart AICD (APP Intra-Cellular Domain) [43].

Although the majority of AD cases are sporadic, a significant fraction of AD is inherited in a dominant pattern. Mutations in the genes encoding for APP and for Presenilin-1 and -2 (PS1 and PS2), two proteins belonging to the γ-secretase enzymatic complex, have been linked to the familial form of AD (FAD; see [44] for a recent review). Since the majority of FAD mutations have been found to increase the Aβ42/Aβ40 ratio, the initial hypothesis was that the disease was dependent on the enhanced fibrillization of the more amyloidogenic Aβ42 [45].

Although this concept has never been questioned, about a decade ago various experimental observations suggested that an alteration in intracellular Ca^{2+} homeostasis could also contribute to the development of FAD, and more in general to the pathogenesis of AD. Indeed, PSs mutations were shown to alter the expression, or the sensitivity, of ER Ca^{2+} release channels (RyR and IP_3R) in different cell models [46–49] and in neurons from Tg AD mice [50,51], leading to the "Ca^{2+} overload" hypothesis [45,52], i.e. the idea that exaggerated ER Ca^{2+} release affects cellular targets such as mitochondria, favouring cellular demise (Fig. 2). The Ca^{2+} overload mechanism has however remained largely mysterious until it was found that wt PSs, but not the FAD mutants, can form Ca^{2+} permeable leak channels in the ER [53, 54], thus providing a clear case for enhanced Ca^{2+} release in the pathological model. Although the data are straightforward, and support a very appealing model, the following work in other laboratories was not entirely consistent with the first formulation of the hypothesis (see for example [55–59]). Specifically, Zatti et al. [60–62] showed that some FAD-linked PS2 mutations caused a reduction, not an increase, in ER/Golgi Ca^{2+} levels. This experimental discrepancy, while not disproving the Ca^{2+} hypothesis, may thus allow two possible conclusions. The first is that the system is likely to be very complex, with additional unidentified regulatory elements, and the use of different cell systems and experimental approaches (e.g. silencing or overexpression, knock-out or knock-in models) may trigger equally different compensatory mechanisms and calcium effects in the cells. Secondly, given that the discrepancies mostly refer to PS2, a speculative, but appealing, possibility is that PS2 and PS1 play distinct roles in ER/Golgi Ca^{2+} handling. In particular, FAD-PS1 mutations, that cause an increase in the ER Ca^{2+}, unavoidably exacerbate cell death. Conversely, PS2 mutants, by favouring low ER Ca^{2+} levels, might confer relative protection to other routes of cell intoxication, such as Aβ peptides and oxidative damage. This hypothesis would be consistent with the above described role of the ER/mitochondrial Ca^{2+} relationship, and with the clinical

observation that FAD-linked PS2 mutations have been associated to milder phenotypes [60–62].

No matter how the synergistic "Ca^{2+} hit" occurs, mitochondrial dysfunction appears an obligatory downstream step in the pathogenesis of AD. Decreased cytochrome *c* oxidase activity, increased free-radical generation leading to oxidative stress and reduced energy metabolism was described in the brain of AD patients before Aβ plaques formation [63–67]. Moreover, electron microscopy analysis of mitochondria in various regions of AD brain revealed significant morphological organelle alterations, such as reduced size of mitochondrial cristae [68].

As to the mechanism, converging evidence points to a role for Aβ peptides and the PTP and, possibly, to a Ca^{2+}-sensitization step. Endogenous as well as ectopically expressed wt or FAD-linked Swedish APP have been found to localize to mitochondria in different cell types [69–71]. In isolated mitochondria, Aβ peptides were shown to inhibit mitochondrial respiration [72,73] and, in the presence of Ca^{2+}, cause the opening of PTP. The involvement of PTP was further reinforced by the analysis of mouse models in which cyclophilin D, (CypD), the PTP component that binds CsA and renders the channel more sensitive to Ca^{2+}, was knocked out [74,75]. Interestingly, this genetic alteration substantially improves the cognitive abilities of a mouse model of AD and alleviates Aβ-mediated reduction of long-term potentiation [76]. Moreover, intra-mitochondrial Aβ was demonstrated to directly interact with CypD, thus providing a molecular basis for this pathogenic mechanism [76]. Other putative damaging effects of Aβ were reported. In PC12 cells, Aβ blocked the entry of nuclear-encoded proteins into mitochondria causing decreased mitochondrial membrane potential, increased ROS production, oxygen glucose deprivation and altered mitochondrial morphology [77]. In another study, Aβ increased neuronal ROS production, activated mitochondrial fission proteins Drp1 and Fis1 and caused mitochondrial fragmentation [78]. Finally, in the mitochondrial matrix Aβ peptides were shown to interact with and inhibit the activity of mitochondrial Aβ-binding alcohol dehydrogenase (ABAD), leading to mitochondrial oxidative damage, increased carbonylation of mitochondrial proteins and impaired activity of respiratory complexes. Some of these alterations were found to occur in AD mouse models before the development of senile plaques, suggesting that mitochondrial dysfunction is an early event in the pathogenesis of the disease [79].

Thus calcium and mitochondria may represent the common theme linking the various reported aspects of the pathogenesis of AD. Several aspects remain however to be solved, and we wish to point out two crucial ones. The first is a clear understanding of the dysregulation of calcium signalling, as discussed above. The second one refers to the origin of intra-mitochondrial Aβ, if a primary role is attributed to this molecule. Experiments of limited trypsin proteolysis and chemical cross-linking showed that APP interacts with the mitochondrial TIM/TOM protein import complex and its orientation is such that the N-terminal resides inside the mitochondria while the large C-terminal part of the protein faces the cytosol [69,71]. Thus, although the presence within mitochondria of γ-secretase constituents and functional γ-secretase activity has been reported [80], it is unlikely that Aβ is being produced on the matrix side. Moreover, the mitochondrial presence of functional β-secretase, essential for the generation of the C99 peptide, substrate for γ-secretase, has not been reported yet. As to direct permeation from the ER, the Golgi complex or secretory vesicles to the cytosol, and then across the outer and the inner mitochondrial membranes (the latter notoriously highly impermeable to most solutes, including ions), this audacious possibility awaits experimental confirmation.

4.2. Huntington's disease (HD)

Huntington's disease (HD) is a progressive neurodegenerative disorder characterized by motor, cognitive and psychiatric symptoms including depression, personality changes, weight loss,

dementia and motor disturbances. The latter are characterized by uncontrolled movements (chorea), developing in the terminal stage into severe akinesia. The disease is inherited in an autosomal dominant fashion and the mutation responsible for the disease was identified as a CAG-triplet expansion in exon 1 of *huntingtin* gene. The CAG sequence codes for glutamine and in HD, an expansion of the polyglutamine (polyQ) stretch beyond 35 glutamines results in pathogenicity and causes the selective death of the GABAergic spiny neurons of the striatum. The length of the polyQ stretch inversely correlates with the age of onset symptoms. Mutant Huntingtin (polyQ-Htt) forms intracellular aggregated, particularly in cell nuclei, and, to a lesser extent, in the cytoplasm, neurites, and terminals [81]. The aggregates have both been suggested to be toxic as well as neuroprotective to the cells. The exact function of Htt is still unknown: it is considered a scaffolding protein mediating protein–protein interactions and to play a role in processes as diverse as axonal transport, regulation of transcription, exocytosis, Ca^{2+} homeostasis, bioenergetic metabolism and prevention of apoptosis [82]. Dysfunctions in any one of these processes could be involved in the etiology of HD. Moreover, a series of seminal, independent observations have highlighted a possible role for Ca^{2+} and mitochondria also in this neurodegenerative disorder (Fig. 3). The first experimental evidence linking neurodegeneration in HD to mitochondrial impairment was the observation that treatment of mice with 3-nitropropionic acid (3-NPA), an inhibitor of complex II of the respiratory chain, induces a degeneration of striatal neurons in vivo, recapitulating HD pathogenesis [83]. In addition, the activities of the respiratory complexes II, III and IV were shown to be reduced in HD [84]. Then, Panov et al. showed that mutant but not wild type Htt directly impairs mitochondrial function. They also proposed that mutant Htt localize on mitochondrial membranes in the neurons of mutant mice, suggesting that a direct relationship may occur between the observed defects and the disease [85]. Finally, Bezprozvanny et al. demonstrated that Htt forms a ternary complex with Htt-associated protein-1A (HAP-1A) and type 1 IP$_3$Rs. In this complex, polyQ-Htt, but not the wild type Htt, facilitates Ca^{2+} release from the ER and renders neurons more sensitive to Ca^{2+}-mediated cellular dysfunction [86]. As to the mechanistic link, mitochondrial Ca^{2+} overload appeared the decisive commitment step [87]. In keeping with this view, Choo et al. showed that mutated, but not wild type, Htt induces PTP opening in isolated mitochondria [88], and we recently demonstrated a facilitated opening of PTP in permeabilized polyQ-Htt expressing cells [89]. Thus, also in this case PTP appears to be the final commitment step in a number of cellular stress conditions, with Ca^{2+} acting as a potent sensitizing factor [89]. As to the stress signals converging on mitochondria, logical candidates are ROS, putatively involved in age-related disorders and in conditions of mitochondrial impairment. Interestingly, the coordinated genomic program mediated by Peroxisome proliferator-activated receptor-coactivator (PGC-1α), a transcription factor that upregulates ROS-scavenging systems upon oxidative stress [90], appears dysfunctional in HD striata [91], and also in cellular models of the disease [92]. Indeed, in both cases the level of the PGC-1α transcript is downregulated, and, at least in part, the scavenging enzymes are accordingly reduced. This observation appears very appealing, as recent work has highlighted PGC-1α transcriptional regulation as a promising drug target [93].

Another important way in which mitochondrial function could be impaired in HD is through abnormal axonal trafficking of mitochondria to and from the synapse. PolyQ-Htt has been proposed to inhibit axonal transport through several mechanisms and, recently, it was shown that fragments of Htt associate with mitochondria thus interfering with their microtubule-associated transport [94]. Overall, the data so far obtained appear very coherent, and highlight a straightforward pathogenic route, based on the triggering of a calcium-dependent mitochondrial dysfunction. What remains to be assessed is how the putative damaging effects of polyQ-Htt are coordinately regulated. Are mitochondrial respiratory deficiencies and calcium-mediated organelle dysfunction two independent effects of mutated Htt, or are they causally linked? Or does the latter gradually induce the former, in a vicious cycle of ROS production and genetic damage that can be further exacerbated by toxic challenges affecting

the brain? And in this picture, why isn't PGC-1α and its anti-oxidant program upregulated? Relative to the respiratory deficiencies, recent work on cultured striatal neurons transfected with a polyQ-Htt showed downregulation of complex II components at the protein, but not at the mRNA, level [95]. Complex II deficiency appears thus due to a post-transcriptional (proteolytic) effect. Whether a calcium-sensitive protease (e.g. calpains) is involved, as was reported in other non genetic models of neurodegeneration [39], has yet to be demonstrated.

4.3. Parkinson's disease (PD)

Parkinson's disease (PD) is a chronic progressive neurodegenerative disorder clinically characterized by motor impairments involving resting tremor, progressive rigidity, bradykinesia and postural instability. PD pathology is characterized most prominently by loss of dopaminergic neurons in the substantia nigra and formation of intraneuronal protein aggregates called Lewy body.

Mitochondrial involvement in PD has been an established notion for many years, since the recognition of the mechanism of action of MPTP (1-methyl 4-phenyl-1,2,3,6-tetrahydropyridine). This compound is formed during production of synthetic heroine, and its metabolite MPP+ is a mitochondrial toxin, that blocks complex I of the respiratory chain. In drug abusers, it causes a form of PD that is clinically indistinguishable from the sporadic variety. Further studies corroborated this observation. Biochemical analysis of PD samples revealed the presence of a mild, systemic defect of complex I, and chronic exposure to the most classical complex I inhibitor (rotenone) accurately recapitulated the pathological, biochemical, and behavioral features of PD. The mechanism of complex I inhibition toxicity probably involves oxidative stress, caused by the block of the respiratory chain, but the selective vulnerability of dopaminergic neurons still remain elusive to explain [96].

The recent identification of a cohort of genes involved in the familial forms of PD further corroborates the notion of mitochondrial involvement, as apparently unrelated proteins seem to share this organelle as a common theme, and possibly point to a signalling role for Ca^{2+} (Fig. 4). Specifically, mutations were reported in genes encoding for α-synuclein, DJ-1, Leucin Rich-Repeated Kinase (LRRK2), ubiquitin C-terminal hydrolase L1 (UCHL1), phosphatase-tensin homologue (PTEN)-induced kinase 1 (PINK1), and parkin, as well as within the mtDNA (for a recent review, see [97]). Mutations in the gene encoding the mitochondrial serine protease HtrA2 have also been linked to PD in several families.

α-synuclein mutations are linked to autosomal dominant familiar PD. Inclusions immunopositive for α-synuclein are found in Levy's body, raising to the possibility that the toxicity of the protein is due to an abnormal form of aggregation or fibril formation, in analogy on what happens in AD. In a recent study [98] the different levels of α-synuclein oligomerization have been linked to cell death. In particular, an heterogeneous mixture of small oligomers of α-synuclein can lead to Ca^{2+} dysregulation, probably via a pore-forming mechanism. Calpain, a major Ca^{2+}-activated protease, can cleave α-synuclein, producing a truncated form more prone to aggregate, thus leading to formation of protofibrils [99]. Overall, these observations suggest that a vicious cycle of Ca^{2+} dysregulation (coordinately activated by the oligomers and, possibly, excitotoxic stimulation) and fibril deposition eventually leads to severe Ca^{2+} overload, to the point of mitochondrial permeability transition and commitment to neuronal cell death.

Parkin has been identified as a ubiquitin-protein ligase (E3) that acts along with the ubiquitin-conjugating enzymes (E2s) in selectivity of ubiquitination and recognition of substrates [100]. Inactivation of parkin leads to reduction in UPS-mediated degradation of its substrates, among which a glycosylated form of α-synuclein. Interestingly, *Drosophila* parkin null mutants exhibited defects in mitochondrial function with signs of increased oxidative stress, muscle

degeneration and male sterility. Reduced levels of mitochondrial proteins involved in mitochondrial oxidative phosphorylation were also reported in parkin-knock-out mice, which exhibited normal brain morphology, but increased striatal extracellular dopamine levels [101]. Overexpression of parkin in cultured cells prevents mitochondrial swelling and stress-induced apoptosis. The protein appears localized in the mitochondrial matrix, where it enhances mitochondrial gene transcription and biogenesis in proliferating cells, but the exact mechanism for the protective function of parkin in mitochondria is unknown [102]. Recently, parkin has been shown to promote the selective clearance of damaged mitochondria through the mitophagic process [103] further reinforcing the concept that it has a neuroprotective role.

PINK1 is highly conserved protein, containing a catalytic serine-threonine kinase domain, ubiquitously expressed in the human brain. It is unambiguously localized to mitochondrial membranes, and its overexpression protects cells from mitochondrial depolarization and apoptosis induced by the proteosomal inhibitor MG132, and from mitochondrially-induced apoptosis triggered by staurosporine [104]. Loss of function mutations are responsible for male sterility, and muscle and dopaminergic neuronal degeneration in *Drosophila* [105]. Overexpression of parkin was shown to rescue the mitochondria dysfunction caused by PINK1 deficiency (but did not rescue the increased sensitivity of PINK1 mutant flies to apoptosis), suggesting that the two proteins could cooperate (probably regulating the balance between mitochondrial fission and fusion, [106]) in preserving mitochondrial integrity in various stress conditions [107]. Interestingly, mutant PINK1 has been shown to exacerbate mitochondrial alterations (disturbing the mitochondrial Ca^{2+} fluxes) promoted by mutant α-synuclein, thus suggesting a cooperative role of these two proteins [108].

LRRK2 is a recently found gene, mutated in familiar late-onset PD. Its product is a kinase [109] and a significant fraction of the protein is associated with mitochondria [110]. Pathogenic PD mutations are linked to activation of the intrinsic apoptotic pathway, with cytochrome c released into the cytosol and activation of caspase-3 [111].

Finally, little is known of the function of the DJ-1 gene product. DJ-1 expression is particularly abundant in brain region where it is largely cytoplasmic except for a pool localized in mitochondria. In particular, DJ-1 was reported to be located in the mitochondrial intermembrane space and in the matrix, while very little, if any, is associated with outer or inner mitochondrial membranes. This finding suggests that DJ-1 may act within mitochondria but its precise neuroprotective mechanism remains obscure (for a review, see [112]). Recent findings suggest that DJ-1 is an atypical peroxiredoxin-like peroxidase [113] indicating that it may play a role in reducing mitochondrial oxidative stress.

These data highlight mitochondria involvement in PD. Obviously, an intriguing possibility is that mitochondrial Ca^{2+} homeostasis, and thus the sensitivity to Ca^{2+}-mediated challenges, are directly or indirectly controlled by these proteins. Work on this topic is under way in several laboratories, including ours, and it is easy to predict that also in this model of neurodegeneration the concerted action of Ca^{2+} and toxic challenges on mitochondria will prove to represent the mechanism leading through time to neuronal dysfunction. Indeed, preliminary evidence from our laboratory, demonstrating an alteration in mitochondrial Ca^{2+} homeostasis in a PD model, supports this possibility. Specifically, by using recombinant aequorin to evaluate Ca^{2+} fluxes [3] we observed an alteration of mitochondrial Ca^{2+} signals in SH-SY5Y cells overexpressing wild type or mutated (G2019S and R1441C) LRRK2, associated with PD (Celsi in preparation).

Overall, the picture emerging from the study of the pathogenesis of the neurodegenerative disorders appears terribly complex, with many uncertainties and gaps to fill. Nevertheless, the common role of mitochondria dysfunction (metabolic, morphologic or dynamic) appears very

clear, and provides not only a leading theme for further studies, but also a promising pharmacological target in these devastating diseases.

Acknowledgments

References

1. Carafoli E. Historical review: mitochondria and calcium: ups and downs of an unusual relationship. Trends Biochem Sci 2003;28:175. [PubMed: 12713900]

2. De Giorgi F, Brini M, Bastianutto C, Marsault R, Montero M, Pizzo P, Rossi R, Rizzuto R. Targeting aequorin and green fluorescent protein to intracellular organelles. Gene 1996;173:113. [PubMed: 8707049]

3. Pinton, P.; Rimessi, A.; Romagnoli, A.; Prandini, A.; Rizzuto, R. Biosensors for the detection of calcium and pH. In: Liza, APaE, editor. Methods in Cell BiologyMitochondria. Vol. 2nd. Academic Press; 2007. p. 297-325.

4. Babcock DF, Herrington J, Goodwin PC, Park YB, Hille B. Mitochondrial participation in the intracellular Ca2+ network. J Cell Biol 1997;136:833. [PubMed: 9049249]

5. Knöpfel T, Dìez-Garcìa J, Akemann W. Optical probing of neuronal circuit dynamics: genetically encoded versus classical fluorescent sensors. Trends Neurosci 2006;29:160. [PubMed: 16443289]

6. Rudolf R, Mongillo M, Rizzuto R, Pozzan T. Looking forward to seeing calcium. Nat Rev Mol Cell Biol 2003;4:579. [PubMed: 12838340]

7. Robb-Gaspers LD, Burnett P, Rutter GA, Denton RM, Rizzuto R, Thomas AP. Integrating cytosolic calcium signals into mitochondrial metabolic responses. EMBO J 1998;17:4987. [PubMed: 9724635]

8. Dedkova EN, Blatter LA. Mitochondrial Ca2+ and the heart. Cell Calcium 2008;44:77. [PubMed: 18178248]

9. Pinton P, Brini M, Bastianutto C, Tuft RA, Pradier L, Rizzuto R. New light on mitochondrial calcium. BioFactors 1998;8:243. [PubMed: 9914826]

10. Rizzuto R, Pozzan T. Microdomains of intracellular Ca2+: molecular determinants and functional consequences. Physiol Rev 2006;86:369. [PubMed: 16371601]

11. Denton RM, McCormack JG. Ca2+ as a second messenger within mitochondria of the heart and other tissues. Annu Rev Physiol 1990;52:451. [PubMed: 2184763]

12. Lasorsa FM, Pinton P, Palmieri L, Fiermonte G, Rizzuto R, Palmieri F. Recombinant expression of the Ca2+-sensitive aspartate/glutamate carrier increases mitochondrial ATP production in agonist-stimulated chinese hamster ovary cells. J Biol Chem 2003;278:38686. [PubMed: 12851387]

13. Jouaville LS, Pinton P, Bastianutto C, Rutter GA, Rizzuto R. Regulation of mitochondrial ATP synthesis by calcium: evidence for a long-term metabolic priming. Proc Natl Acad Sci U S A 1999;96:13807. [PubMed: 10570154]

14. Brini M, Pinton P, King MP, Davidson M, Schon EA, Rizzuto R. A calcium signaling defect in the pathogenesis of a mitochondrial DNA inherited oxidative phosphorylation deficiency. Nat Med 1999;5:951. [PubMed: 10426322]

15. Visch HJ, Rutter GA, Koopman WJH, Koenderink JB, Verkaart S, de Groot T, Varadi A, Mitchell KJ, van den Heuvel LP, Smeitink JAM, Willems PHGM. Inhibition of mitochondrial Na+–Ca2+ exchange restores agonist-induced ATP production and Ca2+ handling in human complex I deficiency. J Biol Chem 2004;279:40328. [PubMed: 15269216]

16. Herzig S, Martinou JC. Mitochondrial dynamics: to be in good shape to survive. Curr Mol Med 2008;8:131. [PubMed: 18336293]

17. Hoek JB, Farber JL, Thomas AP, Wang X. Calcium ion-dependent signalling and mitochondrial dysfunction: mitochondrial calcium uptake during hormonal stimulation in intact liver cells and its

implication for the mitochondrial permeability transition. Biochim Biophys Acta 1995;1271:93. [PubMed: 7599232]

18. Tinel H, Cancela JM, Mogami H, Gerasimenko JV, Gerasimenko OV, Tepikin AV, Petersen OH. Active mitochondria surrounding the pancreatic acinar granule region prevent spreading of inositol trisphosphate-evoked local cytosolic Ca(2+) signals. EMBO J 1999;18:4999. [PubMed: 10487752]

19. David G, Barrett JN, Barrett EF. Evidence that mitochondria buffer physiological Ca2+ loads in lizard motor nerve terminals. J Physiol 1998;509:59. [PubMed: 9547381]

20. Falcke M, Hudson JL, Camacho P, Lechleiter JD. Impact of mitochondrial Ca2+ cycling on pattern formation and stability. Biophys J 1999;77:37. [PubMed: 10388738]

21. Zimmermann B. Control of InsP3-induced Ca2+ oscillations in permeabilized blowfly salivary gland cells: contribution of mitochondria. J Physiol 2000;525(Pt 3):707–19. [PubMed: 10856123]707

22. Boitier E, Rea R, Duchen MR. Mitochondria exert a negative feedback on the propagation of intracellular Ca2+ waves in rat cortical astrocytes. J Cell Biol 1999;145:795. [PubMed: 10330407]

23. Landolfi B, Curci S, Debellis L, Pozzan T, Hofer AM. Ca2+ homeostasis in the agonist-sensitive internal store: functional interactions between mitochondria and the ER measured in situ in intact cells. J Cell Biol 1998;142:1235. [PubMed: 9732284]

24. Hetz C, Glimcher L. The daily job of night killers: alternative roles of the BCL-2 family in organelle physiology. Trends Cell Biol 2008;18:38. [PubMed: 18077169]

25. Pinton P, Ferrari D, Rapizzi E, Di VF, Pozzan T, Rizzuto R. The Ca2+ concentration of the endoplasmic reticulum is a key determinant of ceramide-induced apoptosis: significance for the molecular mechanism of Bcl-2 action. EMBO J 2001;20:2690. [PubMed: 11387204]

26. Rostovtseva T, Bezrukov S. VDAC regulation: role of cytosolic proteins and mitochondrial lipids. J Bioenerg Biomembranes 2008;40:163.

27. Szabadkai G, Bianchi K, Varnai P, De Stefani D, Wieckowski MR, Cavagna D, Nagy AI, Balla T, Rizzuto R. Chaperone-mediated coupling of endoplasmic reticulum and mitochondrial Ca2+ channels. J Cell Biol 2006;175:901. [PubMed: 17178908]

28. Kirichok Y, Krapivinsky G, Clapham DE. The mitochondrial calcium uniporter is a highly selective ion channel. Nature 2004;427:360. [PubMed: 14737170]

29. Bragadin M, Pozzan T, Azzone GF. Kinetics of Ca2+ carrier in rat liver mitochondria. Biochemistry 1979;18:5972. [PubMed: 42437]

30. Cox DA, Matlib MA. Modulation of intramitochondrial free Ca2+ concentration by antagonists of Na(+)–Ca2+ exchange. Trends Pharmacol Sci 1993;14:408. [PubMed: 8296399]

31. Wingrove DE, Gunter TE. Kinetics of mitochondrial calcium transport. II. A kinetic description of the sodium-dependent calcium efflux mechanism of liver mitochondria and inhibition by ruthenium red and by tetraphenylphosphonium. J Biol Chem 1986;261:15166. [PubMed: 2429966]

32. Bernardi P, Azzone GF. Regulation of Ca2+ efflux in rat liver mitochondria. Role of membrane potential. Eur J Biochem 1983;134:377. [PubMed: 6191982]

33. Azzone GF, Azzi A. Volume changes induced by inorganic phosphate in liver mitochondria. Biochem J 1965;94:10C.

34. Huser J, Rechenmacher CE, Blatter LA. Imaging the permeability pore transition in single mitochondria. Biophys J 1998;74:2129. [PubMed: 9545072]

35. Petronilli V, Miotto G, Canton M, Brini M, Colonna R, Bernardi P, Di LF. Transient and long-lasting openings of the mitochondrial permeability transition pore can be monitored directly in intact cells by changes in mitochondrial calcein fluorescence. Biophys J 1999;76:725. [PubMed: 9929477]

36. Szalai G, Krishnamurthy R, Hajnoczky G. Apoptosis driven by IP(3)-linked mitochondrial calcium signals. EMBO J 1999;18:6349. [PubMed: 10562547]

37. Bernardi P, Petronilli V. The permeability transition pore as a mitochondrial calcium release channel: a critical appraisal. J Bioenerg Biomembr 1996;28:131. [PubMed: 9132411]

38. Olney JW. Brain lesions, obesity, and other disturbances in mice treated with monosodium glutamate. Science 1969;164:719. [PubMed: 5778021]

39. Bano D, Young KW, Guerin CJ, Lefeuvre R, Rothwell NJ, Naldini L, Rizzuto R, Carafoli E, Nicotera P. Cleavage of the plasma membrane Na+/Ca2+ exchanger in excitotoxicity. Cell 2005;120:275. [PubMed: 15680332]

40. Mattson MP. Calcium and neurodegeneration. Aging Cell 2007;6:337. [PubMed: 17328689]

41. Scorrano L, Oakes SA, Opferman JT, Cheng EH, Sorcinelli MD, Pozzan T, Korsmeyer SJ. BAX and BAK regulation of endoplasmic reticulum Ca2+: a control point for apoptosis. Science 2003;300:135. [PubMed: 12624178]

42. Chami M, Prandini A, Campanella M, Pinton P, Szabadkai G, Reed JC, Rizzuto R. Bcl-2 and Bax exert opposing effects on Ca2+ signaling, which do not depend on their putative pore-forming region. J Biol Chem 2004;279:54581. [PubMed: 15485871]

43. Thinakaran G, Koo EH. Amyloid precursor protein trafficking, processing, and function. J Biol Chem 2008;283:29615. [PubMed: 18650430]

44. Bertram L, Tanzi RE. Thirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses. Nat Rev Neurosci 2008;9:768. [PubMed: 18802446]

45. Thinakaran G, Sisodia SS. Presenilins and Alzheimer disease: the calcium conspiracy. Nat Neurosci 2006;9:1354. [PubMed: 17066063]

46. Guo Q, Furukawa K, Sopher BL, Pham DG, Xie J, Robinson N, Martin GM, Mattson MP. Alzheimer's PS-1 mutation perturbs calcium homeostasis and sensitizes PC12 cells to death induced by amyloid beta-peptide. NeuroReport 1996;8:379. [PubMed: 9051814]

47. Leissring MA, Parker I, LaFerla FM. Presenilin-2 mutations modulate amplitude and kinetics of inositol 1, 4,5-trisphosphate-mediated calcium signals. J Biol Chem 1999;274:32535. [PubMed: 10551803]

48. Chan SL, Mayne M, Holden CP, Geiger JD, Mattson MP. Presenilin-1 mutations increase levels of ryanodine receptors and calcium release in PC12 cells and cortical neurons. J Biol Chem 2000;275:18195. [PubMed: 10764737]

49. Lee SY, Hwang DY, Kim YK, Lee JW, Shin IC, Oh KW, Lee MK, Lim JS, Yoon DY, Hwang SJ, Hong JT. PS2 mutation increases neuronal cell vulnerability to neurotoxicants through activation of caspase-3 by enhancing of ryanodine receptor-mediated calcium release. FASEB J 2006;20:151. [PubMed: 16394273]

50. Leissring MA, Parker I, LaFerla FM. Presenilin-2 mutations modulate amplitude and kinetics of inositol 1, 4,5-trisphosphate-mediated calcium signals. J Biol Chem 1999;274:32535. [PubMed: 10551803]

51. Smith IF, Green KN, LaFerla FM. Calcium dysregulation in Alzheimer's disease: recent advances gained from genetically modified animals. Cell Calcium 2005;38:427. [PubMed: 16125228]

52. LaFerla FM. Calcium dyshomeostasis and intracellular signalling in Alzheimer's disease. Nat Rev Neurosci 2002;3:862. [PubMed: 12415294]

53. Tu H, Nelson O, Bezprozvanny A, Wang Z, Lee SF, Hao YH, Serneels L, De SB, Yu G, Bezprozvanny I. Presenilins form ER Ca2+ leak channels, a function disrupted by familial Alzheimer's disease-linked mutations. Cell 2006;126:981. [PubMed: 16959576]

54. Nelson O, Tu H, Lei T, Bentahir M, De SB, Bezprozvanny I. Familial Alzheimer disease-linked mutations specifically disrupt Ca2+ leak function of presenilin 1. J Clin Invest 2007;117:1230. [PubMed: 17431506]

55. Kasri NN, Kocks SL, Verbert L, Hebert SS, Callewaert G, Parys JB, Missiaen L, De SH. Up-regulation of inositol 1,4,5-trisphosphate receptor type 1 is responsible for a decreased endoplasmic-reticulum Ca2+ content in presenilin double knock-out cells. Cell Calcium 2006;40:41. [PubMed: 16675011]

56. Green KN, Demuro A, Akbari Y, Hitt BD, Smith IF, Parker I, LaFerla FM. SERCA pump activity is physiologically regulated by presenilin and regulates amyloid beta production. J Cell Biol 2008;181:1107. [PubMed: 18591429]

57. Busche MA, Eichhoff G, Adelsberger H, Abramowski D, Wiederhold KH, Haass C, Staufenbiel M, Konnerth A, Garaschuk O. Clusters of hyperactive neurons near amyloid plaques in a mouse model of Alzheimer's disease. Science 2008;321:1686. [PubMed: 18802001]

58. Cheung KH, Shineman D, Muller M, Cardenas C, Mei L, Yang J, Tomita T, Iwatsubo T, Lee VM, Foskett JK. Mechanism of Ca2+ disruption in Alzheimer's disease by presenilin regulation of InsP3 receptor channel gating. Neuron 2008;58:871. [PubMed: 18579078]

59. Fedrizzi L, Lim D, Carafoli E, Brini M. Interplay of the Ca2+-binding protein DREAM with presenilin in neuronal Ca2+ signaling. J Biol Chem 2008;283:27494. [PubMed: 18664571]

60. Giacomello M, Barbiero L, Zatti G, Squitti R, Binetti G, Pozzan T, Fasolato C, Ghidoni R, Pizzo P. Reduction of Ca2+ stores and capacitative Ca2+ entry is associated with the familial Alzheimer's disease presenilin-2 T122R mutation and anticipates the onset of dementia. Neurobiol Dis 2005;18:638. [PubMed: 15755689]

61. Zatti G, Burgo A, Giacomello M, Barbiero L, Ghidoni R, Sinigaglia G, Florean C, Bagnoli S, Binetti G, Sorbi S, Pizzo P, Fasolato C. Presenilin mutations linked to familial Alzheimer's disease reduce endoplasmic reticulum and Golgi apparatus calcium levels. Cell Calcium 2006;39:539. [PubMed: 16620965]

62. Zatti G, Ghidoni R, Barbiero L, Binetti G, Pozzan T, Fasolato C, Pizzo P. The presenilin 2 M239I mutation associated with familial Alzheimer's disease reduces Ca2+ release from intracellular stores. Neurobiol Dis 2004;15:269. [PubMed: 15006697]

63. Nunomura A, Perry G, Aliev G, Hirai K, Takeda A, Balraj EK, Jones PK, Ghanbari H, Wataya T, Shimohama S, Chiba S, Atwood CS, Petersen RB, Smith MA. Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol 2001;60:759. [PubMed: 11487050]

64. Parker WD Jr. Cytochrome oxidase deficiency in Alzheimer's disease. Ann N Y Acad Sci 1991;640:59. [PubMed: 1663716]

65. Maurer I, Zierz S, Moller HJ. A selective defect of cytochrome c oxidase is present in brain of Alzheimer disease patients. Neurobiol Aging 2000;21:455. [PubMed: 10858595]

66. Lin MT, Beal MF. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 2006;443:787. [PubMed: 17051205]

67. Reddy PH, Beal MF. Are mitochondria critical in the pathogenesis of Alzheimer's disease? Brain Res Brain Res Rev 2005;49:618. [PubMed: 16269322]

68. Baloyannis SJ. Mitochondrial alterations in Alzheimer's disease. J Alzheimers Dis 2006;9:119. [PubMed: 16873959]

69. Anandatheerthavarada HK, Biswas G, Robin MA, Avadhani NG. Mitochondrial targeting and a novel transmembrane arrest of Alzheimer's amyloid precursor protein impairs mitochondrial function in neuronal cells. J Cell Biol 2003;161:41. [PubMed: 12695498]

70. Keil U, Bonert A, Marques CA, Scherping I, Weyermann J, Strosznajder JB, Muller-Spahn F, Haass C, Czech C, Pradier L, Muller WE, Eckert A. Amyloid beta-induced changes in nitric oxide production and mitochondrial activity lead to apoptosis. J Biol Chem 2004;279:50310. [PubMed: 15371443]

71. Park HJ, Kim SS, Seong YM, Kim KH, Goo HG, Yoon EJ, Min dS, Kang S, Rhim H. Beta-amyloid precursor protein is a direct cleavage target of HtrA2 serine protease. Implications for the physiological function of HtrA2 in the mitochondria. J Biol Chem 2006;281:34277. [PubMed: 16968707]

72. Casley CS, Land JM, Sharpe MA, Clark JB, Duchen MR, Canevari L. Beta-amyloid fragment 25–35 causes mitochondrial dysfunction in primary cortical neurons. Neurobiol Dis 2002;10:258. [PubMed: 12270688]

73. Crouch PJ, Blake R, Duce JA, Ciccotosto GD, Li QX, Barnham KJ, Curtain CC, Cherny RA, Cappai R, Dyrks T, Masters CL, Trounce IA. Copper-dependent inhibition of human cytochrome *c* oxidase by a dimeric conformer of amyloid-beta1–42. J Neurosci 2005;25:672. [PubMed: 15659604]

74. Nakagawa T, Shimizu S, Watanabe T, Yamaguchi O, Otsu K, Yamagata H, Inohara H, Kubo T, Tsujimoto Y. Cyclophilin D-dependent mitochondrial permeability transition regulates some necrotic but not apoptotic cell death. Nature 2005;434:652. [PubMed: 15800626]

75. Schinzel AC, Takeuchi O, Huang Z, Fisher JK, Zhou Z, Rubens J, Hetz C, Danial NN, Moskowitz MA, Korsmeyer SJ. Cyclophilin D is a component of mitochondrial permeability transition and mediates neuronal cell death after focal cerebral ischemia. Proc Natl Acad Sci U S A 2005;102:12005. [PubMed: 16103352]

76. Du H, Guo L, Fang F, Chen D, Sosunov A, McKhann M, Yan Y, Wang C, Zhang H, Molkentin JD, Gunn-Moore FJ, Vonsattel JP, Arancio O, Chen JX, Yan SD. Cyclophilin D deficiency attenuates mitochondrial and neuronal perturbation and ameliorates learning and memory in Alzheimer's disease. Nat Med 2008;14:1097. [PubMed: 18806802]

77. Sirk D, Zhu Z, Wadia JS, Shulyakova N, Phan N, Fong J, Mills LR. Chronic exposure to sub-lethal beta-amyloid (Abeta) inhibits the import of nuclear-encoded proteins to mitochondria in differentiated PC12 cells. J Neurochem 2007;103:1989. [PubMed: 17868329]

78. Barsoum MJ, Yuan H, Gerencser AA, Liot G, Kushnareva Y, Graber S, Kovacs I, Lee WD, Waggoner J, Cui J, White AD, Bossy B, Martinou JC, Youle RJ, Lipton SA, Ellisman MH, Perkins GA, Bossy-Wetzel E. Nitric oxide-induced mitochondrial fission is regulated by dynamin-related GTPases in neurons. EMBO J 2006;25:3900. [PubMed: 16874299]

79. Manczak M, Anekonda TS, Henson E, Park BS, Quinn J, Reddy PH. Mitochondria are a direct site of A beta accumulation in Alzheimer's disease neurons: implications for free radical generation and oxidative damage in disease progression. Hum Mol Genet 2006;15:1437. [PubMed: 16551656]

80. Hansson CA, Frykman S, Farmery MR, Tjernberg LO, Nilsberth C, Pursglove SE, Ito A, Winblad B, Cowburn RF, Thyberg J, Ankarcrona M. Nicastrin, presenilin, APH-1, and PEN-2 form active gamma-secretase complexes in mitochondria. J Biol Chem 2004;279:51654. [PubMed: 15456764]

81. Sapp E, Schwarz C, Chase K, Bhide PG, Young AB, Penney J, Vonsattel JP, Aronin N, DiFiglia M. Huntingtin localization in brains of normal and Huntington's disease patients. Ann Neurol 1997;42:604. [PubMed: 9382472]

82. Cattaneo E, Zuccato C, Tartari M. Normal huntingtin function: an alternative approach to Huntington's disease. Nat Rev Neurosci 2005;6:919. [PubMed: 16288298]

83. Brouillet E, Jacquard C, Bizat N, Blum D. 3-Nitropropionic acid: a mitochondrial toxin to uncover physiopathological mechanisms underlying striatal degeneration in Huntington's disease. J Neurochem 2005;95:1521. [PubMed: 16300642]

84. Milakovic T, Johnson GV. Mitochondrial respiration and ATP production are significantly impaired in striatal cells expressing mutant huntingtin. J Biol Chem 2005;280:30773. [PubMed: 15983033]

85. Panov AV, Gutekunst CA, Leavitt BR, Hayden MR, Burke JR, Strittmatter WJ, Greenamyre JT. Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. Nat Neurosci 2002;5:731. [PubMed: 12089530]

86. Tang TS, Tu H, Chan EY, Maximov A, Wang Z, Wellington CL, Hayden MR, Bezprozvanny I. Huntingtin and huntingtin-associated protein 1 influence neuronal calcium signaling mediated by inositol-(1,4,5) triphosphate receptor type 1. Neuron 2003;39:227. [PubMed: 12873381]

87. Bezprozvanny I, Hayden MR. Deranged neuronal calcium signaling and Huntington disease. Biochem Biophys Res Commun 2004;322:1310. [PubMed: 15336977]

88. Choo YS, Johnson GV, MacDonald M, Detloff PJ, Lesort M. Mutant huntingtin directly increases susceptibility of mitochondria to the calcium-induced permeability transition and cytochrome c release. Hum Mol Genet 2004;13:1407. [PubMed: 15163634]

89. Lim D, Fedrizzi L, Tartari M, Zuccato C, Cattaneo E, Brini M, Carafoli E. Calcium homeostasis and mitochondrial dysfunction in striatal neurons of Huntington disease. J Biol Chem 2008;283:5780. [PubMed: 18156184]

90. St-Pierre J, Drori S, Uldry M, Silvaggi JM, Rhee J, Jager S, Handschin C, Zheng K, Lin J, Yang W, Simon DK, Bachoo R, Spiegelman BM. Suppression of reactive oxygen species and neurodegeneration by the PGC-1 transcriptional coactivators. Cell 2006;127:397. [PubMed: 17055439]

91. Weydt P, Pineda VV, Torrence AE, Libby RT, Satterfield TF, Lazarowski ER, Gilbert ML, Morton GJ, Bammler TK, Strand AD, Cui L, Beyer RP, Easley CN, Smith AC, Krainc D, Luquet S, Sweet IR, Schwartz MW, La Spada AR. Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1alpha in Huntington's disease neurodegeneration. Cell Metab 2006;4:349. [PubMed: 17055784]

92. Cui L, Jeong H, Borovecki F, Parkhurst CN, Tanese N, Krainc D. Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell 2006;127:59. [PubMed: 17018277]

93. Arany Z, Wagner BK, Ma Y, Chinsomboon J, Laznik D, Spiegelman BM. Gene expression-based screening identifies microtubule inhibitors as inducers of PGC-1alpha and oxidative phosphorylation. Proc Natl Acad Sci U S A 2008;105:4721. [PubMed: 18347329]

94. Orr AL, Li S, Wang CE, Li H, Wang J, Rong J, Xu X, Mastroberardino PG, Greenamyre JT, Li XJ. N-terminal mutant huntingtin associates with mitochondria and impairs mitochondrial trafficking. J Neurosci 2008;28:2783. [PubMed: 18337408]

95. Majumder P, Raychaudhuri S, Chattopadhyay B, Bhattacharyya NP. Increased caspase-2, calpain activations and decreased mitochondrial complex II activity in cells expressing exogenous huntingtin exon 1 containing CAG repeat in the pathogenic range. Cell Mol Neurobiol 2007;27:1127. [PubMed: 17902043]

96. Greenamyre JT, Sherer TB, Betarbet R, Panov AV. Complex I and Parkinson's disease. IUBMB Life 2001;52:135. [PubMed: 11798025]

97. Schapira AH. Mitochondria in the aetiology and pathogenesis of Parkinson's disease. Lancet Neurol 2008;7:97. [PubMed: 18093566]

98. Danzer KM, Haasen D, Karow AR, Moussaud S, Habeck M, Giese A, Kretzschmar H, Hengerer B, Kostka M. Different species of alpha-synuclein oligomers induce calcium influx and seeding. J Neurosci 2007;27:9220. [PubMed: 17715357]

99. Dufty BM, Warner LR, Hou ST, Jiang SX, Gomez-Isla T, Leenhouts KM, Oxford JT, Feany MB, Masliah E, Rohn TT. Calpain-cleavage of alpha-synuclein: connecting proteolytic processing to disease-linked aggregation. Am J Pathol 2007;170:1725. [PubMed: 17456777]

100. Dawson TM. Parkin and defective ubiquitination in Parkinson's disease. J Neural Transm Suppl 2006:209. [PubMed: 17017531]

101. Palacino JJ, Sagi D, Goldberg MS, Krauss S, Motz C, Wacker M, Klose J, Shen J. Mitochondrial dysfunction and oxidative damage in parkin-deficient mice. J Biol Chem 2004;279:18614. [PubMed: 14985362]

102. Jiang H, Ren Y, Zhao J, Feng J. Parkin protects human dopaminergic neuroblastoma cells against dopamine-induced apoptosis. Hum Mol Genet 2004;13:1745. [PubMed: 15198987]

103. Narendra D, Tanaka A, Suen DF, Youle RJ. Parkin is recruited selectively to impaired mitochondria and promotes their autophagy. J Cell Biol 2008;183:795. [PubMed: 19029340]

104. Wood-Kaczmar A, Gandhi S, Yao Z, Abramov AS, Miljan EA, Keen G, Stanyer L, Hargreaves I, Klupsch K, Deas E, Downward J, Mansfield L, Jat P, Taylor J, Heales S, Duchen MR, Latchman D, Tabrizi SJ, Wood NW. PINK1 is necessary for long term survival and mitochondrial function in human dopaminergic neurons. PLoS ONE 2008;3:e2455. [PubMed: 18560593]

105. Park J, Lee SB, Lee S, Kim Y, Song S, Kim S, Bae E, Kim J, Shong M, Kim JM, Chung J. Mitochondrial dysfunction in *Drosophila* PINK1 mutants is complemented by parkin. Nature 2006;441:1157. [PubMed: 16672980]

106. Deng H, Dodson MW, Huang H, Guo M. The Parkinson's disease genes pink1 and parkin promote mitochondrial fission and/or inhibit fusion in *Drosophila*. Proc Natl Acad Sci U S A 2008;105:14503. [PubMed: 18799731]

107. Yang Y, Gehrke S, Imai Y, Huang Z, Ouyang Y, Wang JW, Yang L, Beal MF, Vogel H, Lu B. Mitochondrial pathology and muscle and dopaminergic neuron degeneration caused by inactivation of *Drosophila* Pink1 is rescued by Parkin. Proc Natl Acad Sci U S A 2006;103:10793. [PubMed: 16818890]

108. Marongiu R, Spencer B, Crews L, Adame A, Patrick C, Trejo M, Dallapiccola B, Valente EM, Masliah E. Mutant Pink1 induces mitochondrial dysfunction in a neuronal cell model of Parkinson's disease by disturbing calcium flux. J Neurochem. 2009

109. West AB, Moore DJ, Biskup S, Bugayenko A, Smith WW, Ross CA, Dawson VL, Dawson TM. Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc Natl Acad Sci U S A 2005;102:16842. [PubMed: 16269541]

110. Biskup S, Moore DJ, Celsi F, Higashi S, West AB, Andrabi SA, Kurkinen K, Yu SW, Savitt JM, Waldvogel HJ, Faull RL, Emson PC, Torp R, Ottersen OP, Dawson TM, Dawson VL. Localization of LRRK2 to membranous and vesicular structures in mammalian brain. Ann Neurol 2006;60:557. [PubMed: 17120249]

111. Iaccarino C, Crosio C, Vitale C, Sanna G, Carri MT, Barone P. Apoptotic mechanisms in mutant LRRK2-mediated cell death. Hum Mol Genet 2007;16:1319. [PubMed: 17409193]

112. Dodson MW, Guo M. Pink1, Parkin, DJ-1 and mitochondrial dysfunction in Parkinson's disease. Curr Opin Neurobiol 2007;17:331. [PubMed: 17499497]

113. Andres-Mateos E, Perier C, Zhang L, Blanchard-Fillion B, Greco TM, Thomas B, Ko HS, Sasaki M, Ischiropoulos H, Przedborski S, Dawson TM, Dawson VL. DJ-1 gene deletion reveals that DJ-1 is an atypical peroxiredoxin-like peroxidase. Proc Natl Acad Sci U S A 2007;104:14807. [PubMed: 17766438]

Fig. 1.
Schematic map of mitochondrial Ca^{2+} transporters. Mitochondria accumulate Ca^{2+} in the matrix via an electrogenic Ca^{2+} uniporter (MCU) that acts to equilibrate Ca^{2+} according the electrochemical gradient generated by the respiratory chain (ETC). Voltage Dependent Anion Channel (VDAC) controls the Ca^{2+} diffusion through the outer mitochondrial membrane (OMM), thus facilitating mitochondrial Ca^{2+} accumulation. As to the efflux pathways, a Na^+/Ca^{2+} and a H^+/Ca^{2+} exchangers have been shown to operate. The permeability transition pore (PTP) opening plays different roles: its brief opening could allow rapid Ca^{2+} release, but its long-lasting openings (potentiated by apoptotic stimuli and Ca^{2+} itself) could trigger cell death process. IMS, intermembrane space; IMM, inner mitochondrial membrane.

Fig. 2.
Presenilins (PSs), Amyloid Precursor Protein (APP) and peptide β-amyloid (Aβ) can affect mitochondrial functionality by different means. FAD-linked PSs mutations may alter the expression/sensitivity of ER Ca^{2+} release channels (RyR and IP_3R) leading to an exaggerated ER Ca^{2+} release that in turn may cause abnormal mitochondrial Ca^{2+} uptake. wt PSs, but not the FAD mutants, were reported to form Ca^{2+} permeable leak channels in the ER providing a clear explanation for the enhanced Ca^{2+} release found in different AD models. APP can interact with the mitochondrial TIM/TOM protein import complex. The presence of an acidic domain within APP sequence may be responsible for an incomplete mitochondrial translocation that, in turn, inhibited the entry of nuclear-encoded mitochondrial proteins. Mitochondrial Aβ accumulation has been correlated with impaired enzymatic activities of cytochrome *c* oxidase (Cyt c-OX) and inhibition of mitochondrial Aβ-binding alcohol dehydrogenase (ABAD), leading to mitochondrial oxidative damage. Intra-mitochondrial Aβ was demonstrated to directly interact with cyclophilin D (CypD), the PTP component that binds CsA and renders the channel more sensitive to Ca^{2+}, making AD mitochondria more sensitive to PTP opening. The origin of intra-mitochondrial Aβ peptides is however unclear. ER, endoplasmic reticulum; OMM outer mitochondrial membrane. IMS, intermembrane space; IMM, inner mitochondrial membrane.

Fig. 3.
Mutant Huntingtin (mutHtt) impairs mitochondrial function by transcriprional and non-trascriptional mechanisms. The transcriptional effects are mediated by nuclear translocation of mutHtt. One important consequence of the regulation of gene transcription is the downregulation of PGC1α, and thus the reduced expression of nuclear-encoded mitochondrial proteins involved in the respiratory chains and in the oxidative-stress defense. MutHtt also associates with the outer mitochondrial membrane (OMM) directly affecting the PTP opening susceptibility and making striatal neurons more vulnerable to excitotoxic stimuli. MutHtt reduces complex II activity and the treatment with the complex II inhibitor 3-nitropropionic acid (3-NPA) induces striatal neurodegeneration in vitro and in vivo. The association of mutHtt with HAP-1A and with the IP3R type I facilitates ER Ca^{2+} release, thus making mitochondria more susceptible to Ca^{2+} overload. ER, endoplasmic reticulum; IMS, intermembrane space; IMM, inner mitochondrial membrane.

Fig. 4.
Mutations in familial PD-linked genes encoding α-synuclein (α-syn), parkin, pink1, DJ-1 and LRRK2 cause mitochondrial dysfunctions through common intersecting pathways. Mutant α-syn promotes Ca^{2+} influx and mitochondrial Ca^{2+} overload and mutant parkin exacerbates this effect. DJ-1, PINK1 and Parkin may act in series on the same protein targets: genetic data suggest that pink1 is upstream of parkin, and that all of them exert a protective role preserving mitochondrial functions, morphology and preventing mitochondrial-induced apoptosis. LRRK2 mutations induce apoptotic death through cytochrome c release and activation of caspase-3. Complex I activity is reduced in PD and its inhibition by MPTP or rotenone causes dopaminergic degeneration. Mutations in mtDNA-encoded complex I subunits also cause PD. PM, plasma membrane; OMM outer mitochondrial membrane; IMS, intermembrane space; IMM, inner mitochondrial membrane.